Stock Price & Analysis

Based on strong analyst sentiment, solid financial performance, and strategic growth initiatives, SYK is a buy. The stock's slight pullback presents a favorable entry point.

The price prediction for SYK stock in 2025 is expected to reach $429 to $450. This forecast is supported by strong earnings performance, strategic acquisitions like the NARI deal, and positive analyst sentiment. Analysts have set high price targets, with several firms rating it a "Strong Buy," indicating significant upside potential.

The S1 support level for SYK Stock is $362.84 ,The R1 resistant level for SYK Stock is $378.81.

As of the end of day on 2025-04-01, the price of SYK Stock was $373.3.

The target price for SYK Stock according to analyst rating is 435.30, with the highest price target at 465.00 and the lowest at 400.00. Analysts have a Strong Buy rating on SYK Stock overall.

The market cap of SYK is $142.5B.

Analysis and Insights

Valuation Metrics

Stryker Corp (SYK) currently has a P/E ratio of 38.73 and an EV/EBITDA of 23.83, both of which are higher than industry averages, suggesting potential overvaluation. The price-to-sales ratio of 6.14 further indicates a premium valuation compared to its peers.

Revenue and Profitability

While Stryker has shown consistent revenue growth, with Q4 2024 revenue reaching $6.436 billion, net income declined to $546 million from $834 million in Q3 2024. This raises concerns about margin compression and profitability trends.

Analyst Sentiment

Analysts maintain a "Strong Buy" or "Buy" rating, with price targets ranging from $418 to $450. However, the current price of $372.59 is nearing the upper end of these targets, limiting immediate upside potential.

Options Market Insight

The $370 put and $380 call contracts reflect moderate volatility, with a 62% chance the put could expire worthless and a 48% chance for the call. This suggests uncertainty in the near term.

Conclusion

Given the high valuation multiples, recent profit decline, and limited upside to analyst targets, Stryker Corp appears overvalued at current levels. Investors should exercise caution and consider waiting for a pullback or improved profitability before entering.

Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. The Company operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Stryker is also engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Stryker's geographical segments include the United States and the International.

Stryker Corp (SYK) is expected to reach a price of $600 by 2030, driven by its strong growth in medical technology and recent strategic acquisitions. Analysts predict sustained growth due to its diversified business and positive market outlook. The stock is currently trading at $372.59, with a Fibonacci resistance level of $378.40, indicating potential upside.

SYK has a total of 52000 employees.